Form 8-K/A

ARCA biopharma, Inc.

(Registrant)

Date: May 9, 2013

/s/ Christopher D. Ozeroff

Name: Christopher D. Ozeroff

Title: SVP & General Counsel

0001193125-13-211348.txt : 20130509 0001193125-13-211348.hdr.sgml : 20130509 20130509170055 ACCESSION NUMBER: 0001193125-13-211348 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20130502 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing FILED AS OF DATE: 20130509 DATE AS OF CHANGE: 20130509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ARCA biopharma, Inc. CENTRAL INDEX KEY: 0000907654 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 363855489 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-22873 FILM NUMBER: 13829745 BUSINESS ADDRESS: STREET 1: 8001 ARISTA PLACE STREET 2: SUITE 200 CITY: BROOMFIELD STATE: CO ZIP: 80021 BUSINESS PHONE: 720-940-2200 MAIL ADDRESS: STREET 1: 8001 ARISTA PLACE STREET 2: SUITE 200 CITY: BROOMFIELD STATE: CO ZIP: 80021 FORMER COMPANY: FORMER CONFORMED NAME: NUVELO INC DATE OF NAME CHANGE: 20030203 FORMER COMPANY: FORMER CONFORMED NAME: HYSEQ INC DATE OF NAME CHANGE: 19970610 8-K/A 1 d536123d8ka.htm FORM 8-K/A Form 8-K/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K/A

(Amendment No. 1)

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): May 9, 2013 (May 2, 2013)

ARCA biopharma, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware

000-22873

36-3855489

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

8001 Arista Place, Suite 430, Broomfield, CO 80021

(Address of Principal Executive Offices) (Zip Code)

(720) 940-2200

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As previously disclosed in a Form 8-K filed on May 6, 2013, Burton E. Sobel, a member of the board of directors of ARCA biopharma, Inc. (“ARCA”), died on May 2, 2013.

ARCA notified The NASDAQ Stock Market LLC (“NASDAQ”) on May 6, 2013 of Dr. Sobel’s death. As a result of his death, ARCA no longer has at least three audit committee members, as required by NASDAQ Listing Rule 5605(c)(2)(A).

Consistent with the cure period provided in NASDAQ Listing Rule 5605(c)(4)(B), ARCA expects to cure this deficiency before the earlier of the Company’s next annual stockholders’ meeting or May 2, 2014.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.